First Hawaiian Bank Sells 3,090 Shares of Boston Scientific Corporation $BSX

Key Points

• First Hawaiian Bank has reduced its shareholding in Boston Scientific Corporation by 6.7%, now holding 42,757 shares valued at approximately $4.31 million.
• Several hedge funds have recently made new investments in Boston Scientific, indicating strong institutional interest, with 89.07% of the stock owned by institutional investors.
• Analysts have a generally positive outlook on Boston Scientific, with multiple firms increasing their price targets and the stock receiving an average rating of "Buy" and a consensus price target of $118.04.

First Hawaiian Bank trimmed its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 6.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,757 shares of the medical equipment provider's stock after selling 3,090 shares during the period. First Hawaiian Bank's holdings in Boston Scientific were worth $4,313,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of BSX. Brighton Jones LLC raised its position in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares during the period. Bank Pictet & Cie Europe AG raised its position in shares of Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after acquiring an additional 21,173 shares during the period. Highview Capital Management LLC DE raised its position in shares of Boston Scientific by 6.2% in the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock valued at $2,189,000 after acquiring an additional 1,439 shares during the period. Gotham Asset Management LLC raised its position in shares of Boston Scientific by 43.7% in the 4th quarter. Gotham Asset Management LLC now owns 11,430 shares of the medical equipment provider's stock valued at $1,021,000 after acquiring an additional 3,475 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Boston Scientific by 6.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 321,764 shares of the medical equipment provider's stock valued at $28,740,000 after acquiring an additional 18,146 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock valued at $18,397,457 over the last three months. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Down 1.6%

Shares of BSX traded down $1.63 during mid-day trading on Friday, hitting $102.71. 10,541,837 shares of the company's stock were exchanged, compared to its average volume of 6,378,869. The company has a market cap of $152.19 billion, a PE ratio of 61.14, a P/E/G ratio of 2.47 and a beta of 0.65. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a 50-day simple moving average of $104.86 and a 200 day simple moving average of $102.27. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's quarterly revenue was up 22.8% on a year-over-year basis. During the same period last year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on BSX. Robert W. Baird increased their target price on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Leerink Partners began coverage on Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 target price for the company. Barclays increased their target price on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Finally, Citigroup reissued a "buy" rating and set a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $118.04.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.